NP Life Sciences Health Industry Group Inc.

ACATdata completeness 75%5 fiscal years on file
The thesis, from the filings

NP Life Sciences Health Industry Group Inc. earns about -92% on equity, with a roughly flat share count. The cash-flow models don't apply cleanly here — the ledger says why below. Whether it’s worth owning at today’s price is the last question — and yours to answer, below.

i. The business — what you’d actually own
FigureFY 2019FY 2020FY 2021FY 2022FY 2023
Revenue$43,0001$15,0002$34,9923$102,0024$164,6214
Net income−$108,8275−$131,0656−$65,6777−$18,8568−$2,9358
Operating cash flow−$4,2669−$124,32210−$90,62511$93,87312−$73,60712
Capital expenditure—————
Free cash flow (derived)—————
Total debt—————
Cash & equivalents$242,93313$118,61114$27,98615$121,85916$70,61416
Diluted shares43.0M43.0M43.0M43.0M43.0M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom). A derived or summed figure cites every filing line it was built from.

ii. Your slice — ownership made literal
If you owned
shares
Net assets behind them
$0
your share of equity
Profit it earned you last year
−$0
Free cash flow it threw off
—
Debt you’d be carrying
—

10 shares is a claim on $0 of net worth that earned you −$0 last year.

iii. Is this a good business?
Moat signal · return on equity
-92% avg · 5y
FY19 -46%FY20 -126%FY21 -172%FY22 -98%FY23 -18%

It earned an average -92% on equity over 5 years. Compare that to what it costs to fund the business.

seeing a moat in the numbers →
Management signal · capital allocation
−0% shares · 5y

Share count is roughly flat over 5 years — little dilution, little buyback.

reading capital allocation →

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.6.0
not applicable
only 0 years of FCF (need ≥3) — model not applicable
not applicable
only 0 years of FCF (need ≥3) — model not applicable
not applicable
normalized (5y-median) earnings non-positive — EPV undefined
not applicable
diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Beyond this page

This page is free, and so is every other company on MeritValue.

In your AI assistant

Connect the MeritValue MCP server to Claude or another MCP client, ask about NP Life Sciences Health Industry Group Inc., and get these exact figures with their filing receipts — not an improvised DCF.

Get a free key →
Screen by model

Pull the companies with a published value under any model (up to 500 a request, filtered by data completeness) into your own sheet or agent. Screening is what Analyst adds, at $9/month.

See pricing →
On iPhone

Follow ACAT and keep your own price beside the value. The same engine, with the same receipts.

MeritValue on the App Store →
Sources — the receipts
  1. 10-K filed 2021-04-15 · period ending 2019-12-31 · accession 0001493152-21-008899 (RevenueFromContractWithCustomerExcludingAssessedTax)
  2. 10-K filed 2022-04-15 · period ending 2020-12-31 · accession 0001493152-22-010074 (RevenueFromContractWithCustomerExcludingAssessedTax)
  3. 10-K filed 2023-04-18 · period ending 2021-12-31 · accession 0001493152-23-012632 (RevenueFromContractWithCustomerExcludingAssessedTax)
  4. 10-K filed 2024-04-16 · periods ending 2022-12-31, 2023-12-31 · accession 0001493152-24-014774 (RevenueFromContractWithCustomerExcludingAssessedTax)
  5. 10-K filed 2021-04-15 · period ending 2019-12-31 · accession 0001493152-21-008899 (NetIncomeLoss)
  6. 10-K filed 2022-04-15 · period ending 2020-12-31 · accession 0001493152-22-010074 (NetIncomeLoss)
  7. 10-K filed 2023-04-18 · period ending 2021-12-31 · accession 0001493152-23-012632 (NetIncomeLoss)
  8. 10-K filed 2024-04-16 · periods ending 2022-12-31, 2023-12-31 · accession 0001493152-24-014774 (NetIncomeLoss)
  9. 10-K filed 2021-04-15 · period ending 2019-12-31 · accession 0001493152-21-008899 (NetCashProvidedByUsedInOperatingActivities)
  10. 10-K filed 2022-04-15 · period ending 2020-12-31 · accession 0001493152-22-010074 (NetCashProvidedByUsedInOperatingActivities)
  11. 10-K filed 2023-04-18 · period ending 2021-12-31 · accession 0001493152-23-012632 (NetCashProvidedByUsedInOperatingActivities)
  12. 10-K filed 2024-04-16 · periods ending 2022-12-31, 2023-12-31 · accession 0001493152-24-014774 (NetCashProvidedByUsedInOperatingActivities)
  13. 10-K filed 2021-04-15 · period ending 2019-12-31 · accession 0001493152-21-008899 (CashAndCashEquivalentsAtCarryingValue)
  14. 10-K filed 2022-04-15 · period ending 2020-12-31 · accession 0001493152-22-010074 (CashAndCashEquivalentsAtCarryingValue)
  15. 10-K filed 2023-04-18 · period ending 2021-12-31 · accession 0001493152-23-012632 (CashAndCashEquivalentsAtCarryingValue)
  16. 10-K filed 2024-04-16 · periods ending 2022-12-31, 2023-12-31 · accession 0001493152-24-014774 (CashAndCashEquivalentsAtCarryingValue)